Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Pressemeddelelse

BioStock: Saniona's CEO comments on the recent news

Saniona

Saniona is advancing its treatments for epilepsy and neurological disorders, with SAN2355 - a selective epilepsy therapy - now in GMP-manufacturing and toxicology studies, aiming for a clinical trial application by late 2025. Meanwhile, Saniona and Acadia Pharmaceuticals has completed two phase I MAD cohorts for ACP-711, formerly SAN711, confirming its safety in healthy volunteers. In addition, from March 18 to April 1, 2025, Saniona's TO4 warrant program could raise up to SEK 188.4 million. We spoke with CEO Thomas Feldthus to learn more.

Read the full interview with Thomas Feldthus at biostock.se:

https://www.biostock.se/en/2025/03/sanionas-ceo-comments-on-the-recent-news/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.